Aerie reports net loss for fourth quarter, full year
Aerie Pharmaceuticals reported a GAAP net loss of $10.3 million, or $0.62 per share, for the fourth quarter ending Dec. 31, 2013, bringing the year-end GAAP net loss to $31.6 million, or $6.38 per share, according to a press release.
GAAP net loss was $3.8 million, or $4.01 per share, and $15.6 million, or $16.39 per share, for the respective time periods the prior year.
Aerie reported being on track with clinical programs for triple-action ophthalmic solution candidate AR-13324 and quadruple-action ophthalmic solution candidate PG324. Proposed trade names for the solutions are Rhopressa and Roclatan, respectively.
Phase 3 trials of Rhopressa are expected to begin early in the third quarter, with efficacy data projected to be available in the middle of 2015. A phase 2b study of Roclatan is under way, with efficacy data projected to be available later this year.